Roche Products Limited
$6.1M 124 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. reported $6,136,179.72 across General Payments, Research, and Ownership to 3,134 physicians and teaching hospitals across 3,984 transactions.
- $6.1M Top quartile payer
- All-tracks total
- 3,984 Top quartile volume
- Transactions
- 3,134 Top quartile reach
- Recipients
- +$229.8K
- General Payments vs PY2023
Agios Pharmaceuticals, Inc. reported $6,136,179.72 across all CMS Open Payments tracks (General + Research + Ownership) to 3,134 physicians and teaching hospitals in Program Year 2024 - ranking #238 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,512,676.91, averaging $2.0K per recipient.
How Agios Pharmaceuticals, Inc.'s $6.1M all-tracks total breaks down
Agios Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
60/100
Total payments
C
67/100
Transaction volume
F
39/100
Physician reach
F
34/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer agios-pharmaceuticals-inc Agios Pharmaceuticals, Inc.
$6.1M · #238/1,925 · 0.0% industry · PY2024
- TOT $6.1M
- RANK #238
- SHARE 0.0%
- TXN 3,984
- RCP 3,134
- CAT 8
- GEN $1.5M
- ΔGEN +$229.8K
- TOP1 27.3%
- PY 2024
Volume peers
Nearest volume peer: Roche Products Limited ($6.1M)
Agios Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Agios Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $229.8K (+17.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AGIOS PHARMACEUTICALS, INC.PY2023: AGIOS PHARMACEUTICALS, INC.PY2024: Agios Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,282,842.32
- PY2024
- $1,512,676.91
What the Data Shows for Agios Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Agios Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
16 transactions worth $760.2K make "Compensation for Services Other Than Consulting" the top general-payment category in the 8-category breakdown below, 50.3% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 8 types of general payments, Agios Pharmaceuticals, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $760.2K - 50.3% of General Payments.
Agios Pharmaceuticals, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (50.3%), Consulting Fee (20.5%), and Honoraria (11.0%). The remaining 5 categories make up 18.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Agios Pharmaceuticals, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Agios Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $760.2K | 16 | 50.3% |
| Consulting Fee | $309.5K | 88 | 20.5% |
| Honoraria | $166.3K | 72 | 11.0% |
| Space Rental or Facility Fees | $104.5K | 16 | 6.9% |
| Food and Beverage | $90.4K | 2,711 | 6.0% |
| Grant | $45.0K | 2 | 3.0% |
| Travel and Lodging | $34.1K | 75 | 2.3% |
| Education | $2.7K | 154 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $957,805.92 (63.3%) of $1,512,676.91 in this company's General Payments records across 2,215 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Agios Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
David Scadden
$412,619.67 across 8 reported transactions
- 2
David Schenkein
$403,125.00 across 5 reported transactions
- 3
Scripps Mercy Hospital
$49,750.00 across 3 reported transactions
- 4
Matthew Vander Heiden
$48,000.00 across 11 reported transactions
- 5
Sherif Badawy
$44,311.25 across 28 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Agios Pharmaceuticals, Inc. ranks #238 of 1,925 by total payments (top 12% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #854 of 1,838 by HHI (top 46% most concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Endotronix, Inc. : $38.2K total payments, HHI 1550
- Krystal Biotech Inc : $202.7K total payments, HHI 1544
- Lucid Diagnostics Inc. : $203.3K total payments, HHI 1539
- MIM Software Inc. : $67.1K total payments, HHI 1538
- Genesis Software Innovations, LLC : $10.8K total payments, HHI 1538
- OCULUS, Inc. : $204.0K total payments, HHI 1529
- Agios Pharmaceuticals, Inc. (this company) : $1.5M total payments, HHI 1523
- Stratus Medical, LLC : $83.5K total payments, HHI 1522
- TrackX Technology, Inc. : $44.2K total payments, HHI 1521
- Encore Medical, LP : $19.8M total payments, HHI 1521
- Kaneka Medical America LLC : $200.8K total payments, HHI 1518
- Histosonics, Inc. : $640.9K total payments, HHI 1514
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Agios Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Agios Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Agios Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sobi, Inc
$6.1M 16,390 recipients
Compare payment profiles
Davol Inc.
$6.2M 12,178 recipients
Compare payment profiles
Tandem Diabetes Care, Inc.
$6.1M 9,526 recipients
Compare payment profiles
CooperVision Inc.
$6.2M 29,989 recipients
Compare payment profiles
Dental Buying Power LLC
$6.2M 0 recipients
Compare payment profiles
Put this to use
Agios Pharmaceuticals, Inc. ranks #238 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Agios Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Agios Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.